Cover Image
市場調查報告書

脂質調節藥的全球市場的成長:趨勢及預測(2017年∼2022年)

Global Lipid Regulators Market Growth, Trends & Forecast (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 391364
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
脂質調節藥的全球市場的成長:趨勢及預測(2017年∼2022年) Global Lipid Regulators Market Growth, Trends & Forecast (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 205 Pages
簡介

脂質調節藥,用作血脂異常症、心血管障礙、骨質疏鬆症、更年期後的併發症等的治療。因此,脂質調整藥大部分分類在處方藥等級。根據調查,每年有2億5,540萬件以上這樣的這些他汀類藥物調劑。完全及非他汀類藥物的脂質調節藥活化他汀類藥物市場。

本報告提供全球脂質調節藥市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 關於報告
  • 調查方法

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 市場成長要素
    • 日益積極的指南
    • 治療人口的增加
    • 高齡人口
    • 進行中的治療藥的需求
    • 病人依從性改善
    • 政府的輔助
  • 市場阻礙因素
    • 對脂質調節藥的認識低
    • 未遵守醫生的NCEP指南
    • 複合藥的引進
    • 低成本非專利的引進
  • 市場機會
  • 市場威脅

第4章 波特五力分析

  • 供應商談判力
  • 買主談判力
  • 競爭度
  • 替代品的威脅
  • 新加入廠商的威脅

第5章 市場區隔

  • 各類型
    • 他汀類
    • 非他汀類
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
      • 印度
      • 中國
      • 日本
      • 新加坡
      • 其他

第6章 競爭情形

第7章 企業簡介

  • Abbott Laboratories
  • Andrx Corporation
  • Astrazeneca
  • Atellas Pharma, Inc.
  • Bristol-Myers Squibb
  • Bentley Pharmaceuticals
  • Merck
  • Novartis
  • Pfizer
  • Teva Pharmaceuticals

第8章 附錄

  • 簡稱
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

The Global Market for Lipid Regulators accounted for $XX billion in 2014 and the market size is estimated to grow up to $XX billion by 2020 with CAGR at XX%.

Lipid regulators or lipid-regulating drugs are used to treat dyslipidemias, cardiovascular problems, osteoporosis and post-menopause complications. This is why these lipid regulators come under class of most prescribed medications. A study reveals that more than 255.4 million prescriptions are being filled each year for these statins. Lipid regulators including a full range of statin and non-statin products energize the statin market.

The segmentation of the global market for lipid regulators is based majorly on the Types (statins and non-statins) and Geographical Regions. Statins further include sub-segments like branded statins, statin combinations and generic statins, while non-statins are sub-divided into fibric-acid derivatives, bile-acid sequestrants, nicotinic acid derivatives and other new products.

North America leads the global market for lipid regulators followed by Europe. However, the developing countries like India and China are contributing to the revenues of this market, there by positioning Asia Pacific in the list of top regions holding larger share for lipid regulators market. This can be due to increasing incidences of diseases and increasing demand for advancing therapeutics.

The key players for this market include Abbott Laboratories, Andrx Corporation, Astrazeneca, Atellas Pharma, Inc., Bristol-Myers Squibb, Pfizer, Novartis, Merck, Teva Pharmaceuticals and Bentley Pharmaceuticals among others.

Drivers

Increasingly aggressive guidelines fuel up statin market. The increasing number of treatment population, aging population, demand for advancing therapeutics, improved patient compliance and government support are the other factors driving this market.

Restraints

Low awareness of Lipid Regulators mainly restrains the global market potential. In addition, non-adherence to National Cholesterol Education Program (NCEP) guidelines by physicians, introduction of combination drugs and introduction of low cost generics

What the report offers?

1) Market Definition for the specified topic along with identification of key drivers and restraints for the market.

2) Market analysis for the Global Lipid Regulators Market in Healthcare Industry, with region specific assessments and competition analysis on a global and regional scale.

3) Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

4) Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

5)Identification and analysis of the Macro and Micro factors that affect the Global Lipid Regulators Market in Healthcare Industry on both global and regional scale.

6) A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

D

Table of Contents

1. Introduction

  • 1.1 Report Description
  • 1.2 Research Methodology

2. Executive Summary

3. Market Overview

  • 3.1 Market Definition
  • 3.2 Market Drivers
    • 3.2.1 Increasingly aggressive guidelines
    • 3.2.2 Increasing number of treatment population
    • 3.2.3 Aging population
    • 3.2.4 Demand for advancing therapeutics
    • 3.2.5 Improved patient compliance
    • 3.2.6 Government support
  • 3.3 Market restraints
    • 3.3.1 Low awareness of Lipid Regulators
    • 3.3.2 Non-adherence to NCEP guidelines by physicians
    • 3.3.3 Introduction of combination drugs
    • 3.3.4 Introduction of low cost generics
  • 3.4 Market Opportunitites
  • 3.5 Market Threats

4. Porters Five Force Analysis

  • 4.1 Bargaining Power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Degree of competition
  • 4.4 Threat of substitution
  • 4.5 Threat of new entrants

5. Market Segmentation

  • 5.1 By Type
    • 5.1.1 Statins
      • 5.1.1.1 Branded statins
      • 5.1.1.2 Statin combinations
      • 5.1.1.3 Generic statins
    • 5.1.2 Non-statins
      • 5.1.2.1 Fibric-acid derivatives
      • 5.1.2.2 Bile-acid sequestrants
      • 5.1.2.3 Nicotinic acid derivatives
      • 5.1.2.4 Other new products
  • 5.2 By Geography
    • 5.2.1 North America
      • 5.2.1.1 US
      • 5.2.1.2 Canada
    • 5.2.2 Europe
      • 5.2.2.0 France
      • 5.2.2.1 UK
      • 5.2.2.2 Germany
      • 5.2.2.3 Scandinavian Regions
      • 5.2.2.4 Italy
      • 5.2.2.5 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3..1 India
    • 5.2.3..2 China
    • 5.2.3..3 Japan
    • 5.2.3..4 Singapore
    • 5.2.4 Rest of Asia Pacific

6. Competitive Landscape

7. Company Profiles

  • 7.1 Abbott Laboratories
  • 7.2 Andrx Corporation
  • 7.3 Astrazeneca
  • 7.4 Atellas Pharma, Inc.
  • 7.5 Bristol-Myers Squibb
  • 7.6 Bentley Pharmaceuticals
  • 7.7 Merck
  • 7.8 Novartis
  • 7.9 Pfizer
  • 7.10 Teva Pharmaceuticals

8. Appendix

  • 8.1 Abbrevations
  • 8.3 Bibliography
  • 8.4 Disclaimer
Back to Top